Publications by authors named "Monica Passannante"

Bloodstream infections (BSI) are frequent complications after allogeneic hematopoietic cell transplant (HCT). This study reports data on pre-engraftment BSI in years 2016-2021 and analyses changes in incidence, aetiology, resistance and mortality compared with two previous periods (2004-2009 and 2010-2015). In years 2004-2021, 1364 patients received HCT.

View Article and Find Full Text PDF

CAR CD4 T cell lymphopenia is an emerging issue following CAR-T cell therapy. We analyzed the determinants of CD4 T cell recovery and a possible association with survival in 31 consecutive patients treated with commercial CAR-T for diffuse large B-cell (DLBCL) or mantle cell lymphoma. Circulating immune subpopulations were characterized through multiparametric-flow cytometry.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which is impaired in heavily pre-treated HL patients. Here, we aimed to enhance the activity of early post-ASCT CI (nivolumab) administration with the infusion of autologous lymphocytes (ALI).

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed minimal residual disease (MRD) in 224 AML patients before undergoing stem cell transplants to evaluate their risk of relapse.
  • It highlighted that combining MRD assessment techniques offered strong prognostic insights, categorizing patients into three different risk groups for relapse.
  • Findings indicated that negative combined MRD status and myeloablative conditioning significantly improved overall survival, suggesting MRD evaluation could guide treatment strategies for high-risk patients.
View Article and Find Full Text PDF
Article Synopsis
  • * A study examined the impact of a BPDCN-like phenotype on the prognosis of younger patients with cytogenetically normal acute myeloblastic leukemia (AML), revealing that 18% exhibited this phenotype.
  • * The BPDCN-like phenotype did not significantly affect survival in the overall group but was linked to a worse prognosis in AML patients with mutated NPM1.
View Article and Find Full Text PDF

Acute myeloid leukemia with biallelic mutation of CEBPA (CEBPA-dm AML) is a distinct good prognosis entity recognized by WHO 2016 classification. However, testing for CEBPA mutation is challenging, due to the intrinsic characteristics of the mutation itself. Indeed, molecular analysis cannot be performed with NGS technique and requires Sanger sequencing.

View Article and Find Full Text PDF